NO974943L - Angiostatinfragmenter, aggregert angiostatin og anvendelse derav - Google Patents

Angiostatinfragmenter, aggregert angiostatin og anvendelse derav

Info

Publication number
NO974943L
NO974943L NO974943A NO974943A NO974943L NO 974943 L NO974943 L NO 974943L NO 974943 A NO974943 A NO 974943A NO 974943 A NO974943 A NO 974943A NO 974943 L NO974943 L NO 974943L
Authority
NO
Norway
Prior art keywords
angiostatin
fragments
proliferation inhibitor
aggregated
aggregate
Prior art date
Application number
NO974943A
Other languages
English (en)
Norwegian (no)
Other versions
NO974943D0 (no
Inventor
Moses Judah Folkman
Michael S O'reilly
Yihai Cao
Jie Lin
Original Assignee
Childrens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/429,743 external-priority patent/US5885795A/en
Priority claimed from US08/605,598 external-priority patent/US5861372A/en
Priority claimed from US08/612,788 external-priority patent/US5837682A/en
Application filed by Childrens Medical Center filed Critical Childrens Medical Center
Publication of NO974943D0 publication Critical patent/NO974943D0/no
Publication of NO974943L publication Critical patent/NO974943L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO974943A 1995-04-26 1997-10-24 Angiostatinfragmenter, aggregert angiostatin og anvendelse derav NO974943L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/429,743 US5885795A (en) 1994-04-26 1995-04-26 Methods of expressing angiostatic protein
US08/605,598 US5861372A (en) 1996-02-22 1996-02-22 Aggregate angiostatin and method of use
US08/612,788 US5837682A (en) 1996-03-08 1996-03-08 Angiostatin fragments and method of use
PCT/US1996/005856 WO1996035774A2 (en) 1995-04-26 1996-04-26 Angiostatin fragments and aggregate angiostatin and methods of use

Publications (2)

Publication Number Publication Date
NO974943D0 NO974943D0 (no) 1997-10-24
NO974943L true NO974943L (no) 1997-12-18

Family

ID=27411639

Family Applications (1)

Application Number Title Priority Date Filing Date
NO974943A NO974943L (no) 1995-04-26 1997-10-24 Angiostatinfragmenter, aggregert angiostatin og anvendelse derav

Country Status (16)

Country Link
EP (1) EP0824546B1 (de)
JP (2) JP3787157B2 (de)
CN (1) CN1195375A (de)
AT (1) ATE368051T1 (de)
AU (1) AU709633B2 (de)
BR (1) BR9608326A (de)
CA (1) CA2219081C (de)
CZ (1) CZ334097A3 (de)
DE (1) DE69637179T2 (de)
ES (1) ES2292174T3 (de)
HU (1) HUP9800784A3 (de)
MX (1) MX9708217A (de)
NO (1) NO974943L (de)
NZ (1) NZ307044A (de)
PL (1) PL323256A1 (de)
WO (1) WO1996035774A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945403A (en) * 1997-05-30 1999-08-31 The Children's Medical Center Corporation Angiostatin fragments and method of use
US6358735B1 (en) 1995-06-30 2002-03-19 University Of Kansas Medical Center Method for inhibiting angiogenesis and tumors with the isolated NC1 α3 chain monomer of type IV collagen
US6440729B1 (en) 1995-06-30 2002-08-27 University Of Kansas Medical Center Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagen
KR100477280B1 (ko) * 1995-12-13 2005-07-18 아보트 러보러터리즈 맥관형성에의한질환치료제
US5801012A (en) 1996-09-17 1998-09-01 Northwestern University Methods and compositions for generating angiostatin
EP1019515A1 (de) * 1997-10-01 2000-07-19 G.D. SEARLE & CO. Fusionsproteinen mit einem angiostatin-anteil und deren anwendung in antitumortherapie
WO1999026480A1 (en) * 1997-11-20 1999-06-03 Genetix Pharmaceuticals, Inc. Anti-angiogenic gene therapy vectors and their use in treating angiogenesis-related diseases
CN1284134A (zh) * 1997-12-08 2001-02-14 贝斯以色列护理医疗中心 利用毕赤氏酵母表达系统生产抗生血管蛋白质∶制管张素,内抑制素或静息蛋白的方法
US6797488B1 (en) 1997-12-08 2004-09-28 Beth Israel Deaconess Medical Center Methods of producing anti-angiogenic proteins
CA2263784A1 (en) 1998-03-23 1999-09-23 Megabios Corporation Dual-tagged proteins and their uses
EP1074264B1 (de) * 1998-04-28 2008-09-17 Toshikazu Nakamura Inhibitoren für die gefässneubildung
AU3959499A (en) 1998-05-28 1999-12-13 Korea Green Cross Corporation Process of purifying angiogenesis inhibitors
JP2002518341A (ja) 1998-06-15 2002-06-25 アーチ・デヴェロップメント・コーポレイション 放射線療法と抗血管形成因子の組み合わせ
US6201104B1 (en) * 1998-12-04 2001-03-13 Entremed, Inc. Angiogenesis—inhibiting protein binding peptides and proteins and methods of use
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
WO2000044391A2 (en) * 1999-01-28 2000-08-03 The Children's Medical Center Corporation Plasminogen kringle 4 region fragments and methods of use
US7157556B1 (en) 1999-02-10 2007-01-02 The Children's Medical Center Corporation Deglycosylated kringle 1-3 region fragments of plasminogen and methods of use
AU2990300A (en) * 1999-02-10 2000-08-29 Children's Medical Center Corporation Deglycosylated kringle 1-5 region fragments of plasminogen and methods of use
UY26929A1 (es) * 2000-09-29 2002-04-26 Abbott Lab Polipéptidos antiangiogénicos y métodos para inhibir la angiogénesis
JP2006506321A (ja) * 2002-04-11 2006-02-23 チルドレンズ メディカル センター コーポレーション 血管透過性亢進を阻害する方法
EP1713511B1 (de) * 2004-01-09 2011-11-09 Mogam Biotechnology Research Institute Therapeutisches mittel zur behandlung von krebs mit humanen apolipoprotein (a) kringles lk68 oder lk8 genen als wirksame inhaltsstoffe, und verfahren zur behandlung von krebs damit
JPWO2005079835A1 (ja) * 2004-02-24 2007-08-02 株式会社ティーティーシー Ｂｌアンジオスタチンを含む制がん剤
ITMI20041962A1 (it) * 2004-10-15 2005-01-15 Istituto Naz Per La Ricerca S "peptide di angiostatina e suoi impieghio terapeutici"
CN101219219B (zh) * 2007-01-10 2013-02-13 北京普罗吉生物科技发展有限公司 包含血管抑素或其片段的复合物、其制备方法及应用
WO2010070746A1 (ja) * 2008-12-17 2010-06-24 株式会社ティムス イヌアンジオスタチン様ポリペプチド
JP5749229B2 (ja) * 2012-07-31 2015-07-15 京セラドキュメントソリューションズ株式会社 ジェスチャー管理プログラム及び情報処理装置
CN106890324A (zh) * 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种预防和治疗糖尿病肾病的方法
CN108778307A (zh) 2015-12-18 2018-11-09 泰伦基国际有限公司 一种预防和治疗糖尿病肾病的方法
US11129880B2 (en) 2016-12-15 2021-09-28 Talengen International Limited Method for promoting insulin secretion
WO2019043649A2 (en) * 2017-08-31 2019-03-07 Singapore Health Services Pte Ltd ANGIO -3 FOR THE TREATMENT OF RETINAL ANGIOGENIC DISEASES

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE355379T1 (de) * 1994-04-26 2006-03-15 Childrens Medical Center Angiostatin und verfahren zu seiner nutzung zur vermeidung der angiogenese

Also Published As

Publication number Publication date
ES2292174T3 (es) 2008-03-01
HUP9800784A2 (hu) 1998-07-28
MX9708217A (es) 1997-12-31
CA2219081C (en) 2004-02-24
NZ307044A (en) 2002-03-01
BR9608326A (pt) 2000-03-08
JP3787157B2 (ja) 2006-06-21
JPH11508228A (ja) 1999-07-21
HK1002457A1 (en) 1998-08-28
WO1996035774A2 (en) 1996-11-14
NO974943D0 (no) 1997-10-24
CN1195375A (zh) 1998-10-07
CA2219081A1 (en) 1996-11-14
EP0824546B1 (de) 2007-07-25
HUP9800784A3 (en) 2000-07-28
CZ334097A3 (cs) 1998-04-15
AU5579596A (en) 1996-11-29
AU709633B2 (en) 1999-09-02
ATE368051T1 (de) 2007-08-15
WO1996035774A3 (en) 1997-02-13
JP2001151691A (ja) 2001-06-05
EP0824546A2 (de) 1998-02-25
PL323256A1 (en) 1998-03-16
DE69637179D1 (de) 2007-09-06
DE69637179T2 (de) 2008-04-10

Similar Documents

Publication Publication Date Title
NO974943D0 (no) Angiostatinfragmenter, aggregert angiostatin og anvendelse derav
CA2291892A1 (en) Angiostatin fragments and method of use
EA199800391A1 (ru) Ингибирование роста опухоли антисмысловыми олигонуклеотидами к il-8 и il-8 рецептору
MXPA00004256A (es) Inhibidor de las celulas endoteliales vasculares, un inhibidor de la angiogenesis y crecimiento del tumor.
ATE214075T1 (de) Monoklonale antikörper gegen endoglin und ihre verwendung in der anti-angiogenese-therapie
EA199900162A1 (ru) Ингибиторы клеточной адгезии
DE60015070D1 (de) Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache
NO961888D0 (no) Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer av metallproteinaser
MX342777B (es) Inhibidores tnfa para usarse en el tratamiento de trastornos relacionados con tnfa.
NO990086D0 (no) Avkortete, oppl÷selige tumornekrosefaktorreseptorer av type I og type II
NO20000752L (no) Metode for forhindring eller behandling av østrogen-avhengige sykdommer og forstyrrelser
AU7934900A (en) Method of screening for inhibitors of asp2
DE69620458D1 (de) Benzofuran-carboxamide und -sulfonamide
ATE211921T1 (de) Verwendung von gonadotropin zur behandlung der gestartigen hypertrophie der prostata
NO20003848D0 (no) FremgangsmÕte ved behandling av folikkulært lymfom ved anvendelse av inhibitorer for lymfotoksin (LT)-veien
ATE309352T1 (de) Inhibitoren der nf-kb aktivierung
WO2000044391A3 (en) Plasminogen kringle 4 region fragments and methods of use
NO851518L (no) Monoklonale antistoffer eller fragmenter derav, spesifikke for alfa2-plasmininhibitor
DK0914605T3 (da) Molekylemodel for VLA-4-inhibitorer
CO4920227A1 (es) Histidina-n-bencil glicinamida sustituida con cicloalquilos .
NO951277L (no) Desulfatohirudin med höy molekylvekt
ATE239076T1 (de) Zielspezifische abgabe zum nukleus mittels protein h von streptococcus
DE60034434D1 (de) Deglykosilierte fragmente der kringle 1-5 region von plasminogen und verwendungsverfahren
TR199901543T2 (xx) Benzo $F] kinolinnonlar�n sentezi
TR200003083T2 (tr) CNS hastalıklarının tedavisi için paroxetine 10-camphorsulfonate.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application